Implant agent for treating ophthalmopathy

An implant, eye disease technology, used in the field of medicine

Inactive Publication Date: 2006-03-15
段亚东
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] So far, there are no publications describing the implants for the treatment of eye diseases with trad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1: A drug-releasing tube implant prepared from a non-biodegradable polymer material.

[0080] Take the medical silicone rubber hollow tube, the outer diameter of the silicone rubber hollow tube is 2.5mm, the inner diameter is 2.2mm, the tube wall thickness is 0.3mm, and the length is 30mm. The silicone rubber hollow tube is fumigated and sterilized by formalin for 12 hours. Under sterile conditions, Seal one end of the silicone rubber hollow tube with a medical silicone rubber adhesive, mix 100 mg of anisodine, 100 μg of basic fibroblast growth factor, 1 g of citicoline, and 75 mg of muscone, and mix them into the silicone rubber hollow tube. The other end of the hollow tube of the silicone tube is sealed in the same way. The effective release length of the hollow tube of the silicone rubber is 26mm. Put it in a plastic bag and sterilize it with ethylene oxide for 48 hours before use.

Embodiment 2

[0081] Example 2: A drug-releasing tube implant prepared from a biodegradable polymer material.

[0082] Take the medical polylactic acid hollow tube, the outer diameter of the polylactic acid hollow tube is 2.5mm, the inner diameter is 2.2mm, the tube wall thickness is 0.3mm, and the length is 30mm. The polylactic acid hollow tube was fumigated with formalin for 12 hours. Under sterile conditions, one end of the polylactic acid hollow tube was heat-sealed, and anisodine 100mg, basic fibroblast growth factor 100μg, citicoline 1g , muscone 75mg, after mixing, put into the polylactic acid hollow tube, the other end of the polylactic acid hollow tube is sealed with the same method, put into the plastic bag, standby after 48 hours of ethylene oxide sterilization.

Embodiment 3

[0083] Example 3: The biodegradable polymer material is mixed with the drug, and the implant is prepared by the melting method.

[0084] Put the polylactic acid into a glass dish, heat in water solution, heat and stir continuously until it melts completely, the polylactic acid melts to a viscous fluid state, then add 100mg of anisodine, 1g of citicoline, and 75mg of muscone into the polylactic acid Stir quickly to make the drug evenly disperse in the polylactic acid, cool slightly, pour it into the mold, and drool to form a film. After drying, put the implant into a plastic bag and sterilize it with ethylene oxide. Backup.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Outer diameteraaaaaaaaaa
The inside diameter ofaaaaaaaaaa
Tube wall thicknessaaaaaaaaaa
Login to view more

Abstract

An implant for treating retinosis and optic atrophy is composed of the carrier and the medicine chosen from the Chinese-medicinal vascular dilating medicine, neurotrophic factor and citicoline.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a new slow-release implant for treating eye diseases such as retinal degeneration and optic atrophy. Background technique [0002] Retinal degeneration and optic atrophy are common intractable diseases in ophthalmology, which will eventually lead to blindness. The treatment of this disease is the long-term desire to solve by domestic and foreign medical personnel, but there is no technical problem of success all the time. Ge Jian, editor-in-chief of "National Higher Medical Colleges and Universities 7-year Planning Textbook. Ophthalmology", People's Health Publishing House, published in 2002, page 193 records: "There is no effective treatment for retinitis pigmentosa". At present, there are mainly the following technologies for the treatment of retinal degeneration and optic atrophy: systemic medication is affected by various factors such as blood-ocular barrier, pl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61K38/17A61P27/02A61M31/00
Inventor 段亚东
Owner 段亚东
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap